Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment

Completed

• Conditions: Osteoporosis, Postmenopausal
• Interventions: Other: OPSAT-Q

• Registration Number: NCT01227369
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Detailed Description

Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Study Timeline

• Study Start: 2008-06
• Primary Completion: 2009-11
• Study Completion: 2009-11
• Study First Submitted: 2010-06-03
• Study First Submitted QC: 2010-10-21
• Study First Posted: 2010-10-25
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-06
• Last Update Posted: 2017-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 4376

Inclusion Criteria

• Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation

Exclusion Criteria

• Do not understand the contents of the questionnaire

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Bisphosphonates	OPSAT-Q	Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Primary Outcome Measures

Name	Time	Method
Mean of composite satisfaction score (CSS) of OPSAT-QTM	0day

Secondary Outcome Measures

Name	Time	Method
Mean of subscale satisfaction scores of OPSAT-QTM	oday

Trial Locations

Locations (1)

GSK Investigational Site; 🇰🇷 Seoul, Korea, Republic of